AGL:LSE-ANGLE plc (GBX)

COMMON STOCK | Diagnostics & Research | LSE

Last Closing Price

GBX 95.40

Change

-1.60 (-1.65)%

Market Cap

GBX 0.23B

Volume

0.18M

Avg Analyst Target

GBX 195.00 (+104.40%)

Avg User Target

GBX
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AGL Stock Forecast & Price:
Based on the ANGLE plc stock forecasts from 1 analysts, the average analyst target price for ANGLE plc is GBX 195.00 over the next 12 months. ANGLE plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ANGLE plc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, ANGLE plc’s stock price was GBX 95.40. ANGLE plc’s stock price has changed by +0.32% over the past week, -31.37% over the past month and -25.18% over the last year.

About ANGLE plc (AGL:LSE)

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiple ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MXCL:LSE MaxCyte, Inc

N/A

GBX0.86B N/A N/A
IDHC:LSE Integrated Diagnostics Holding..

-0.01 (-1.86%)

GBX0.46B 6.33 0.13
HZD:LSE Horizon Discovery Group plc

N/A

GBX0.30B N/A N/A
DXRX:LSE Diaceutics PLC

N/A

GBX0.08B 9,150.00 26.81
GENI:LSE Genincode PLC

N/A

GBX0.04B N/A N/A
GDR:LSE genedrive plc

+2.25 (+11.69%)

GBX0.02B N/A -2.07
ABDX:LSE Abingdon Health Plc

+0.50 (+4.55%)

GBX0.01B N/A -1.22
PRM:LSE Proteome Sciences PLC

N/A

GBX0.01B N/A 31.88

ETFs Containing AGL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.83% 83% B 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.83% 83% B 42% F
Trailing 12 Months  
Capital Gain -27.04% 83% B 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.04% 83% B 25% F
Trailing 5 Years  
Capital Gain 64.48% 100% A+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.48% 75% C 85% B
Average Annual (5 Year Horizon)  
Capital Gain 34.85% 71% C- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.85% 57% F 85% B
Risk Return Profile  
Volatility (Standard Deviation) 57.82% 57% F 24% F
Risk Adjusted Return 60.27% 86% B 79% C+
Market Capitalization 0.23B 83% B 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.55 20% F 9% F
Price / Cash Flow Ratio -16.37 100% A+ 89% B+
EV/EBITDA -12.36 100% A+ 87% B+
Management Effectiveness  
Return on Equity -40.21% 60% D- 11% F
Return on Invested Capital -39.86% 50% F 5% F
Return on Assets -24.22% 40% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.67 20% F 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector